Cipher Pharmaceuticals (TSE:CPH) Shares Pass Below Fifty Day Moving Average – Here’s What Happened

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$17.72 and traded as low as C$16.00. Cipher Pharmaceuticals shares last traded at C$16.31, with a volume of 17,402 shares.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group set a C$17.00 target price on shares of Cipher Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of C$17.00.

Cipher Pharmaceuticals Stock Performance

The stock’s 50-day moving average is C$17.72 and its 200-day moving average is C$16.05. The stock has a market cap of C$414.13 million, a price-to-earnings ratio of 13.71 and a beta of 1.10. The company has a current ratio of 1.25, a quick ratio of 2.67 and a debt-to-equity ratio of 0.32.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its earnings results on Thursday, May 7th. The company reported C$0.33 earnings per share (EPS) for the quarter. The firm had revenue of C$17.39 million during the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. On average, analysts expect that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.